Scholarlink

<p>Pediatric oncology continues to see transformative advancements aimed at improving survival rates, reducing long-term side effects, and enhancing the overall quality of life for children with cancer. Recent progress spans therapeutic innovations, technological advancements in tumor tissue and liquid biopsy analyses, and holistic care improvements, reflecting a&#xa0;multidisciplinary approach to childhood cancer treatment. Advances in genomic technologies have enabled the identification of mutations driving pediatric cancers. By targeting these mutations and other molecular targets, personalized treatment protocols can improve response rates and reduce toxicity. Liquid biopsy technologies offer a&#xa0;noninvasive method to detect, monitor, and analyze tumor-derived biomarkers circulating in bodily fluids (e.g., blood, bone marrow, and urine), enabling treatment response monitoring and early relapse diagnosis. Novel immunotherapies including CAR&#xa0;T-cell therapies and monoclonal antibodies have demonstrated success, particularly in leukemia and neuroblastoma. Techniques such as proton beam therapy have enhanced precision radiotherapy in tumor targeting, minimizing damage to surrounding healthy tissues. This is especially critical in pediatric patients, where developmental concerns are paramount. Pediatric oncology care increasingly addresses emotional and psychosocial aspects, providing comprehensive support to children and their families. The growing population of childhood cancer survivors highlights the need for specialized follow-up care. Surveillance for late effects such as secondary cancers, cardiovascular issues, and neurocognitive challenges is critical for improving long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pädiatrische Onkologie: Fortschritte in Diagnostik und Therapie

  • 期刊论文

  • 发表日期：

    2025年1月12日

查看全文
  • Hedwig Deubzer,
  • Anne Thorwarth,
  • Sveva Castelli,
  • Theresa Thole,
  • Franziska Schulze,
  • Annette Künkele,
  • Arend von Stackelberg,
  • Angelika Eggert

摘要

Pediatric oncology continues to see transformative advancements aimed at improving survival rates, reducing long-term side effects, and enhancing the overall quality of life for children with cancer. Recent progress spans therapeutic innovations, technological advancements in tumor tissue and liquid biopsy analyses, and holistic care improvements, reflecting a multidisciplinary approach to childhood cancer treatment. Advances in genomic technologies have enabled the identification of mutations driving pediatric cancers. By targeting these mutations and other molecular targets, personalized treatment protocols can improve response rates and reduce toxicity. Liquid biopsy technologies offer a noninvasive method to detect, monitor, and analyze tumor-derived biomarkers circulating in bodily fluids (e.g., blood, bone marrow, and urine), enabling treatment response monitoring and early relapse diagnosis. Novel immunotherapies including CAR T-cell therapies and monoclonal antibodies have demonstrated success, particularly in leukemia and neuroblastoma. Techniques such as proton beam therapy have enhanced precision radiotherapy in tumor targeting, minimizing damage to surrounding healthy tissues. This is especially critical in pediatric patients, where developmental concerns are paramount. Pediatric oncology care increasingly addresses emotional and psychosocial aspects, providing comprehensive support to children and their families. The growing population of childhood cancer survivors highlights the need for specialized follow-up care. Surveillance for late effects such as secondary cancers, cardiovascular issues, and neurocognitive challenges is critical for improving long-term outcomes.